NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) has cleared a major regulatory hurdle. On September 21, it announced European Commission approval of Ubeslo, containing 10 mg of obicetrapib, and Evlarco, combining 10 mg of obicetrapib with 10 mg of ezetimibe. These are the products’ first global approvals.
The medicines lower low-density lipoprotein cholesterol, or LDL-C, commonly called bad cholesterol. The approvals cover adults with primary high cholesterol or mixed lipid disorders, with treatment eligibility depending on existing therapy and statin tolerance.
Menarini holds exclusive European commercialization rights. NewAmsterdam Pharma Company N.V. is entitled to tiered royalties ranging from low double-digit percentages to the mid-20% range on net sales in the licensed territory. The question now is how quickly an approved treatment can become a meaningful source of recurring revenue.
Bull Case
The clinical proposition combines substantial cholesterol lowering with oral dosing. The approval announcement cites statistically significant LDL-C reductions versus placebo of up to 40% with obicetrapib and approximately 50% with the ezetimibe combination across the supporting Phase 3 program. These studies evaluated patients already receiving maximally tolerated cholesterol-lowering treatment.
That creates a practical opportunity among patients needing additional LDL-C reduction. A tablet containing two medicines could simplify treatment for eligible patients who would otherwise take separate pills. Convenience may support adoption, although sustained use will depend on the patient experience and access.
NewAmsterdam Pharma Company N.V. also enters commercialization with an established partner. Menarini’s cardiovascular expertise and European commercial infrastructure could reduce the need to build a regional sales organization from scratch. Royalties allow participation in sales growth through that existing network.
The agreement provides up to an additional €833 million in potential clinical, regulatory, and commercial milestone payments. Those payments depend on specified achievements, while royalties offer the opportunity for recurring income as prescriptions grow.
Financial resources provide support during the transition. NewAmsterdam Pharma Company N.V. reported $678.3 million in cash, cash equivalents, and marketable securities as of June 30, 2026.
Bear Case
Cholesterol reduction alone does not demonstrate that these products prevent heart attacks or strokes. The ongoing PREVAIL cardiovascular-outcomes trial, which enrolled more than 9,500 patients, is designed to test whether obicetrapib reduces major cardiovascular events. In its August update, NewAmsterdam Pharma Company N.V. planned an interim analysis for the fourth quarter of 2026, with results expected in the first quarter of 2027.
Commercial access is another hurdle. Approval allows marketing, but reimbursement decisions, prescribing restrictions and negotiated prices will determine how many patients receive treatment and the net sales supporting royalties. The September announcement did not specify launch prices or quantify expected royalty revenue.
The partner model also shares the economics. NewAmsterdam Pharma Company N.V. receives a percentage of licensed net sales, and the highest royalty tier should not be assumed across all revenue. Strong prescription growth could still generate modest early royalties if net prices or initial sales volumes are limited.
Development spending continues alongside launch preparations. Second-quarter research and development expenses were $41.7 million, while the net loss was $64.1 million. Approval therefore does not establish near-term profitability.
Hedge Fund Sentiment
The filings available so far reflect positions held before NewAmsterdam Pharma Company N.V. reported its European approvals. Insider Monkey’s database showed 45 hedge funds holding NewAmsterdam Pharma Company N.V. at the end of 2Q2026, up from 34 funds three months earlier.
Conclusion
NewAmsterdam Pharma Company N.V. has moved from seeking European approval to proving commercial demand. Reimbursement, prescribing adoption and realized royalties will show whether the products can build a durable business. PREVAIL adds a separate test of cardiovascular benefit that could strengthen, or constrain, the longer-term opportunity.
READ NEXT: Pan American Silver (PAAS) Updates its Reserve Base. How Much Growth Reflects Better Mines? and Lennar (LEN) Cuts Delivery Forecast. Can Construction Savings Offset Heavy Incentives?
This article is originally published at Insider Monkey.
Hedge Fund Resource Center